A randomized, controlled trial of everolimus-based dual immunosuppression versus standard of care in de novo kidney transplant recipients

Transplant International

Volumn 27, Issue 3, 2014, Pages 302-311

  Chadban, Steven J ^a   Eris, Josette Marie ^a   Kanellis, John ^b   Pilmore, Helen ^c   Lee, Po Chang ^d   Lim, Soo Kun ^e   Woodcock, Chad ^f   Kurstjens, Nicol ^f   Russ, Graeme ^g  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^b MONASH MEDICAL CENTRE   (Australia)

^c AUCKLAND CITY HOSPITAL   (New Zealand)

^d NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

^e UNIVERSITY MALAYA MEDICAL CENTRE   (Malaysia)

^f Medical Department   (Australia)

^g ROYAL ADELAIDE HOSPITAL   (Australia)

Author keywords

cyclosporin; everolimus; kidney transplantation; mammalian target of rapamycin; steroids

Indexed keywords

CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOSPORIN; EVEROLIMUS; IMMUNOSUPPRESSIVE AGENT; MTOR PROTEIN, HUMAN; MYCOPHENOLIC ACID; RAPAMYCIN; TARGET OF RAPAMYCIN KINASE;

ADULT; ADVERSE EFFECTS; AGED; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GLOMERULUS FILTRATION RATE; HEALTH CARE QUALITY; HISTOCOMPATIBILITY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MULTICENTER STUDY; PROCEDURES; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; YOUNG ADULT;

ADRENAL CORTEX HORMONES; ADULT; AGED; CALCINEURIN INHIBITORS; CYCLOSPORINE; EVEROLIMUS; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; PROSPECTIVE STUDIES; SIROLIMUS; STANDARD OF CARE; TOR SERINE-THREONINE KINASES; TRANSPLANTATION IMMUNOLOGY; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84894057854     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/tri.12252     Document Type: Article

References (27)

1. Vincenti F, Friman S, Scheuermann E, et al,. Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus. Am J Transplant 2007; 7: 1506.
2. Clayton P, Campbell S, Hurst K, et al,. ANZDATA 2011 Annual report. Chapter 8 Transplantation. Available via: http://www.anzdata.org.au/v1/report- 2011.html
3. Meier-Kriesche HU, Schold JD, Srinivas TR, et al,. Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant 2004; 4: 378.
4. Nankivell BJ, Borrows RJ, Fung CL, et al,. The natural history of chronic allograft Nephropathy. N Engl J Med 2003; 349: 2326.
5. Pilmore H, Dent H, Chang S, et al,. Reduction in cardiovascular death after kidney transplantation. Transplantation 2010; 89: 851.
6. Vajdic CM, McDonald SP, McCredie MRE, et al,. Cancer incidence before and after kidney transplantation. JAMA 2006; 296: 2823.
7. Burdmann E, Andoh T, Yu L, Bennett W,. Cyclosporine nephrotoxicity. Semin Nephrol 2003; 23: 465.
8. Wong W, Tolkoff-Rubin N, Delmonico F, et al,. Analysis of the cardiovascular risk profile instable kidney transplant recipients after 50% cyclosporine reduction. Clinical Transplant 2004; 18: 341.
9. A blinded, randomised clinical trial of Mycophenolate Mofetil for the prevention of acute rejection in cadaveric renal transplantation (Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group). Transplantation 1996; 61: 1029.
10. Knight SR, Morris PJ,. Steroid avoidance or withdrawal after renal transplantation increases the risk of acute rejection but decreases cardiovascular risk. A meta-analysis. Transplantation 2010; 89: 1.
11. Schuler W, Sedrani R, Cottens S, et al,. SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo. Transplantation 1997; 64: 36.
12. Kahan BD,. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study. The Rapamune US Study Group. Lancet 2000; 356: 194.
13. Baboolal K,. A phase III prospective, randomized study to evaluate concentration-controlled sirolimus (rapamune) with cyclosporine dose minimization or elimination at six months in de novo renal allograft recipients. Transplantation 2003; 75: 1404.
14. Budde K, Becker T, Arns W, et al,. Everolimus-based, calcineurin- inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial. Lancet 2011; 377: 837.
15. Campbell SB, Walker R, Tai SS, Jiang Q, Russ GR,. Randomized controlled trial of sirolimus for renal transplant recipients at high risk for nonmelanoma skin cancer. Am J Transplant 2012; 12: 1146.
16. Euvrard S, Morelon E, Rostaing L, et al,. Sirolimus and secondary skin cancer prevention in kidney transplantation. New Eng J Med 2012; 367: 329.
17. Kreis H, Oberbauer R, Campistol JM, et al,. Long-term benefits with sirolimus-based therapy after early cyclosporine withdrawal. J Am Soc Nephrol 2004; 15: 809.
18. Vitko S, Tedesco H, Eris J, et al,. Everolimus with optimized cyclosporine dosing in renal transplant recipients: 6-month safety and efficacy results of two randomized studies. Am J Transplant 2004; 4: 626.
19. Lebranchu Y, Thierry A, Toupance O, et al,. Efficacy on renal function of early conversion from cyclosporine to sirolimus 3 months after renal transplantation: concept study. Am J Transplant 2009; 9: 1115.
20. Vitko S, Margreiter R, Weimar W, et al,. Everolimus (Certican) 12-month safety and efficacy versus mycophenolate mofetil in de novo renal transplant recipients. Transplantation 2004; 78: 1532.
21. Tedesco H, Cribrick D, Johnston E, et al,. Everolimus plus reduced-exposure CsA versus Mycophenolic acid plus standard-exposure CsA in renal- transplant recipients. Am J Transplant 2010; 10: 1401.
22. Chan L, Greenstein S, Hardy MA, et al,. Multicenter, randomized study of the use of everolimus with tacrolimus after renal transplantation demonstrates its effectiveness. Transplantation 2008; 85: 821.
23. Langer RM, Hene R, Vitko S, et al,. Everolimus plus early tacrolimus minimization: a phase III, randomized, open-label, multicentre trial in renal transplantation. Transplant Int 2012; 25: 592.
24. Flechner SM, Glyda M, Cockfield S, et al,. The ORION study: comparison of two sirolimus-based regimens versus tacrolimus and mycophenolate mofetil in renal allograft recipients. Am J Transplant 2011; 11: 1633.
25. Holdaas H, Bentdal O, Pfeffer P, et al,. Early, abrupt conversion of de novo renal transplant patients from cyclosporine to everolimus: results of a pilot study. Clin Transplant 2008; 22: 366.
26. Kovarik JM, Kalbag J, Figueiredo J, et al,. Differential influence of two cyclosporine formulations on everolimus pharmacokinetics: a clinically relevant pharmacokinetic interaction. J Clin Pharmacol 2002; 42: 95.
27. Ho E, Teo BW,. Assessing kidney function in Asia. Singapore Med J 2010; 51: 888.